Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Public ClinicalTrials.gov record NCT03779854. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multi-Center Phase II Randomized Controlled Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cells before the transplant may stop this from happening.
Study identification
- NCT ID
- NCT03779854
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 45 participants
Conditions and interventions
Conditions
- Acute Biphenotypic Leukemia
- Acute Leukemia
- Acute Leukemia of Ambiguous Lineage
- Acute Lymphoblastic Leukemia
- Acute Undifferentiated Leukemia
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Blasts Under 25 Percent of Bone Marrow Nucleated Cells
- Blasts Under 5 Percent of Bone Marrow Nucleated Cells
- Mixed Phenotype Acute Leukemia
- Myelodysplastic Syndrome With Excess Blasts-1
- Myelodysplastic Syndrome/Acute Myeloid Leukemia
- Burkitt Leukemia
- Chronic Monocytic Leukemia
- Lymphoblastic Lymphoma
- Mast Cell Leukemia
- Myeloproliferative Neoplasm
Interventions
- Total-Body Irradiation Radiation
- Thiotepa Drug
- Fludarabine Drug
- Cyclophosphamide Drug
- Busulfan Drug
- Allogeneic Bone Marrow Transplantation Procedure
- Tacrolimus Drug
- Methotrexate Drug
- Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation Procedure
- Echocardiography Procedure
- Biospecimen Collection Procedure
- Bone Marrow Aspiration Procedure
- Bone Marrow Biopsy Procedure
Radiation · Drug · Procedure
Eligibility (public fields only)
- Age range
- 6 Months to 26 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 28, 2019
- Primary completion
- Dec 30, 2028
- Completion
- Dec 30, 2028
- Last update posted
- Sep 2, 2026
2019 – 2028
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Hospital of Los Angeles | Los Angeles | California | 90027 | — |
| Children's Healthcare of Atlanta | Atlanta | Georgia | 30329 | — |
| University of Iowa/Holden Comprehensive Cancer Center | Iowa City | Iowa | 52242 | — |
| Dana Farber / Boston Children's Hospital | Boston | Massachusetts | 02115 | — |
| UH Rainbow Babies and Children's Hospital (University Hospitals Cleveland Medical Center) | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Children's Hospital of Pittsburgh of UPMC | Pittsburgh | Pennsylvania | 15224 | — |
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03779854, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 2, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03779854 live on ClinicalTrials.gov.